Taro Pharmaceutical Industries Ltd. completed a $250 million share buyback program which was announced in November 2016.
The Israeli pharmaceutical company bought back 2,493,378 ordinary shares at an average price of $100.28 per share.
Israel's Taro completes $250M share buyback program
COVID-19 Pandemic Likely To Cause US Telemedicine Boom
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
Israel's Taro completes $250M share buyback program
- Author Ravikash Bakolia
- Theme Healthcare & Pharmaceuticals
- Author
- Ravikash Bakolia
- Theme
- Healthcare & Pharmaceuticals